OncoGenex to Webcast Update on Clinical Development Program and Discussion of
Fourth Quarter and Full Year 2012 Financial Results on Thursday, March 7, 2013
BOTHELL, WA and VANCOUVER, Feb. 28, 2013
BOTHELL, WA and VANCOUVER, Feb. 28, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth
quarter 2012 financial results will be released on Thursday, March 7, 2013,
and that the Company will host a conference call and live webcast at 4:30 p.m.
ET that afternoon. Management will discuss the company's financial results and
provide an update on the business.
To access the webcast, log on to the Investor Relations page of the OncoGenex
website at www.oncogenex.com. Alternatively, you may access the live
conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313
(International). A webcast replay will be available approximately two hours
after the call and will be archived on www.oncogenex.com for 90 days.
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd.(NYSE:TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in
Phase 2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com.
SOURCE OncoGenex Pharmaceuticals, Inc.
Investor Relations Contact:
Press spacebar to pause and continue. Press esc to stop.